NASDAQ:ACRSAclaris Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aclaris Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.21 -0.07 (-3.07 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$2.20Now: $2.21▼$2.4250-Day Range$1.48MA: $1.94▼$2.4552-Week Range$0.70Now: $2.21▼$3.34Volume15,064 shsAverage Volume870,307 shsMarket Capitalization$94.41 millionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Aclaris Therapeutics. Previous Next 2.6 Community Rank Outperform VotesAclaris Therapeutics has received 335 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAclaris Therapeutics has received 305 “underperform” votes. (Add your “underperform” vote.)Community SentimentAclaris Therapeutics has received 52.34% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote “Outperform” if you believe ACRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.20% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions76.66% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($1.43) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.85 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRS Previous Symbol CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone484-324-7933Debt Debt-to-Equity Ratio0.21 Current Ratio4.00 Quick Ratio4.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.23 million Price / Sales22.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book1.91Profitability EPS (Most Recent Fiscal Year)($2.25) Net Income$-161,350,000.00 Net Margins-1,827.81% Return on Equity-105.38% Return on Assets-62.85%Miscellaneous Employees169 Outstanding Shares42,720,000Market Cap$94.41 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $2.21 -0.07 (-3.07 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ACRS News and Ratings via Email Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions How has Aclaris Therapeutics' stock been impacted by Coronavirus (COVID-19)? Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACRS stock has increased by 108.5% and is now trading at $2.21. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Aclaris Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aclaris Therapeutics. When is Aclaris Therapeutics' next earnings date? Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Aclaris Therapeutics. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its quarterly earnings results on Friday, August, 7th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.08. Aclaris Therapeutics had a negative return on equity of 105.38% and a negative net margin of 1,827.81%. View Aclaris Therapeutics' earnings history. Has Aclaris Therapeutics been receiving favorable news coverage? Media stories about ACRS stock have been trending negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news about Aclaris Therapeutics. Are investors shorting Aclaris Therapeutics? Aclaris Therapeutics saw a increase in short interest in February. As of February 15th, there was short interest totaling 4,050,000 shares, an increase of 18.8% from the January 31st total of 3,410,000 shares. Based on an average daily volume of 713,000 shares, the short-interest ratio is currently 5.7 days. Currently, 12.2% of the company's shares are short sold. View Aclaris Therapeutics' Short Interest. Who are some of Aclaris Therapeutics' key competitors? Some companies that are related to Aclaris Therapeutics include AMAG Pharmaceuticals (AMAG), Passage Bio (IMRA), Progenics Pharmaceuticals (PGNX), Magenta Therapeutics (MGTA), Catalyst Pharmaceuticals (CPRX), Neptune Wellness Solutions (NEPT), Calithera Biosciences (CALA), Beyondspring (BYSI), CytomX Therapeutics (CTMX), Wave Life Sciences (WVE), Geron (GERN), Heat Biologics (HTBX), REDHILL BIOPHAR/S (RDHL), Pivot Pharmaceuticals (PVOTF) and Aeglea Bio Therapeutics (AGLE). View all competitors. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Nabriva Therapeutics (NBRV), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Abeona Therapeutics (ABEO), Aduro BioTech (ADRO) and AVEO Pharmaceuticals (AVEO). Who are Aclaris Therapeutics' key executives? Aclaris Therapeutics' management team includes the following people: Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)Mr. Frank Ruffo, Co-Founder & CFO (Age 53)Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60) What is Aclaris Therapeutics' stock symbol? Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS." Who are Aclaris Therapeutics' major shareholders? Aclaris Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (0.26%), WINTON GROUP Ltd (0.11%) and Virtu Financial LLC (0.09%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, James E Flynn and Stephen A Tullman. View institutional ownership trends for Aclaris Therapeutics. Which institutional investors are selling Aclaris Therapeutics stock? ACRS stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, and WINTON GROUP Ltd. View insider buying and selling activity for Aclaris Therapeutics. Which institutional investors are buying Aclaris Therapeutics stock? ACRS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, and Stephen A Tullman. View insider buying and selling activity for Aclaris Therapeutics. How do I buy shares of Aclaris Therapeutics? Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aclaris Therapeutics' stock price today? One share of ACRS stock can currently be purchased for approximately $2.21. How big of a company is Aclaris Therapeutics? Aclaris Therapeutics has a market capitalization of $94.41 million and generates $4.23 million in revenue each year. The biotechnology company earns $-161,350,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe. What is Aclaris Therapeutics' official website? The official website for Aclaris Therapeutics is www.aclaristx.com. How can I contact Aclaris Therapeutics? Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
